Pancreatic Cancer
Conditions
Brief summary
This study aims to collect clinical, biological and quality of life data from patients with a borderline or resectable pancreatic cancer. It will collect information from the date of diagnosis along the therapeutic care of the patients, and a 3-years follow-up after the end of the treatment. The database will be updated at each patient's visit. Biological samples will include: tumor, and plasma. Epidemiological data will also be collected, whereas Quality of life will be assessed by the EORTC standard. The objectives of this database are to identify new biomarkers (genomic, immunologic, and epidemiologic) and promote high quality standard research protocol.
Interventions
blood and tumor tissue samples
Sponsors
Cancéropôle Grand-Est
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with exocrine resectable pancreatic adenocarcinoma or potentially resectable (that after neoadjuvant treatment are considered appropriate candidates for resection) * Histologically or cytologically documented diagnosis of exocrine pancreatic adenocarcinoma * Written informed consent obtained prior enrollment in the study
Exclusion criteria
* other types of pancreatic cancer, in particular endocrine tumor or acinar cells * ampulloma * metastatic disease * other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer * patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study * patient under guardianship, curator or under the protection of justice.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| disease-free survival according to the consensus DATECAN (Bonnetain F et al, European Journal of Cancer 2014) | date of first disease apparition [within 3 years after the enrollment of the last patient] | DATECAN = Definition for the Assessment of Time-to-event Endpoints in CANcer trials |
Countries
France
Outcome results
None listed